Comparative Pharmacology
Head-to-head clinical analysis: LOTRISONE versus OXICONAZOLE NITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOTRISONE versus OXICONAZOLE NITRATE.
LOTRISONE vs OXICONAZOLE NITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lotrisone combines betamethasone dipropionate, a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, and clotrimazole, an imidazole antifungal that inhibits CYP51 (lanosterol 14alpha-demethylase), disrupting ergosterol synthesis and fungal cell membrane integrity.
Oxiconazole nitrate is an azole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the enzyme lanosterol 14α-demethylase. This leads to increased membrane permeability and cell death.
Apply a thin film to affected skin areas twice daily, morning and evening, for 2 weeks.
Apply a thin layer to affected skin once daily for 2 weeks for tinea pedis, tinea cruris, and tinea corporis.
None Documented
None Documented
Clotrimazole: 3.5-6 hours (topical, minimal systemic absorption); betamethasone dipropionate: approximately 4-6 hours for betamethasone after hydrolysis.
Terminal elimination half-life is approximately 20-30 hours, allowing once-daily or twice-daily topical application.
Clotrimazole: <0.5% of dose excreted unchanged in urine; betamethasone dipropionate: primarily renal (<5% unchanged) and biliary/fecal (35-50% as metabolites).
Primarily biliary/fecal: >75% of dose excreted unchanged and as metabolites in feces via bile; renal excretion accounts for <10% (mostly inactive metabolites).
Category C
Category C
Topical Antifungal/Corticosteroid Combination
Topical Antifungal